Written by The Latent TB Detection Market is expanding as healthcare systems increase efforts to identify latent tuberculosis infection (LTBI) and reduce the risk of progression to active tuberculosis. Detection methods include tuberculin skin tests (TST) and interferon-gamma release assays (IGRAs), which are used across hospitals, diagnostic laboratories, clinics, and public health screening programs. Growing awareness of early TB detection, government initiatives, and the need to screen high-risk populations are supporting demand for latent TB diagnostic solutions.
Technological development is shaping the market through the increasing use of blood-based testing and advanced IGRA platforms. T-SPOT.TB and QuantiFERON-TB Gold are among the detection technologies used in the market, while diagnostic applications include screening and identification of latent infection among populations such as household contacts and people living with HIV. IGRAs are gaining attention because they can provide results during a single patient visit and offer greater specificity in individuals previously vaccinated with Bacille Calmette-Guérin (BCG).
Regional market development is influenced by TB burden, healthcare infrastructure, public health programs, diagnostic access, and investment in infectious-disease testing. Asia-Pacific accounted for the largest share of the global latent tuberculosis infection detection market in 2025, with India identified as a significant country market. The global market was estimated at USD 2.0 billion in 2025 and is projected to reach USD 3.2 billion by 2033, according to Grand View Research. Continued adoption of advanced screening technologies, expansion of TB-control programs, and improvements in diagnostic infrastructure are expected to support market development worldwide.